SCTXScribe Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Scribe Therapeutics, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCTX본 종목 | $620M#1 | — | — | — | — | — | — | — | — | — | — | — |
| CRDF | $100M#2 | — | 3.8x#8 | 169.2x#6 | -13.2%#5 | -0.9%#4 | -8256.3%#6 | -0.2%#4 | — | — | -35.8%#10 | — |
| ATRA | $100M#3 | — | — | 0.8x#2 | -6.3%#4 | 138.3%#1 | 29.7%#1 | — | — | — | -16.2%#4 | — |
| PTHS | $81M#4 | — | — | 4.8x#4 | — | -444.6%#14 | -193.1%#4 | — | — | — | -33.0%#9 | — |
| VXRT | $80M#5 | 2.0x#1 | 1.0x#2 | 0.3x#1 | 726.7%#1 | 124.4%#2 | 7.6%#2 | 0.0%#1 | 22.5%#1 | — | -24.0%#6 | — |
| KLRS | $76M#6 | — | 1.3x#3 | 463.1x#7 | — | 37.2%#3 | -27970.9%#8 | -75.3%#7 | — | — | -27.8%#8 | — |
| ELOX | $75M#7 | 5.2x#2 | 1.6x#4 | — | -100.0%#7 | -90.7%#11 | — | -12.9%#5 | — | — | — | — |
| BSEM | $74M#8 | — | 2.7x#6 | — | — | — | — | 0.0%#2 | — | — | — | — |
| LONA | $68M#10 | — | 2.0x#5 | — | — | -9.3%#5 | — | -315.5%#10 | — | — | 93.0%#2 | — |
| CSBR | $69M#9 | — | 17.6x#10 | 1.2x#3 | 4.4%#3 | -125.0%#13 | -1.9%#3 | -0.0%#3 | — | — | -25.5%#7 | — |
| EXOZ | $60M#11 | — | 16.5x#9 | 861.0x#8 | — | -56.3%#10 | -13867.0%#7 | -250.6%#9 | — | — | -45.8%#12 | — |
| INMB | $59M#13 | — | 2.9x#7 | 1174.0x#9 | 257.1%#2 | -9.5%#6 | -94766.0%#9 | -225.9%#8 | -607.3%#2 | — | 10.2%#3 | — |
| INKT | $59M#12 | — | — | — | — | -15.9%#7 | — | — | — | — | -19.2%#5 | — |
| IMA | $59M#14 | — | 0.4x#1 | 73.4x#5 | -77.1%#6 | -24.0%#8 | -6056.4%#5 | -31.9%#6 | — | — | -39.1%#11 | — |
| BKHAU | $53M#15 | — | — | — | — | -30.6%#9 | — | — | — | — | 133.8%#1 | 96.2%#1 |
| TVGN | $50M#16 | — | — | — | — | -91.4%#12 | — | — | — | — | -81.8%#13 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice